2026年7月,英硅智能自主研发的Rentosertib(ISM001-055)正式启动III期临床试验,成为全球首款由AI发现全新靶点、AI设计全新分子并推进至上市前最后验证阶段的候选药物。同月,公司发布业绩预告,2026年上半年实现扭亏为盈,临床与财务数据双双兑现。 放眼整个AI制药行业,2026年,全球AI驱动的新药临床管线增至179个,9个进入III期,剂泰科技的制剂创新、...
Source Link2026年7月,英硅智能自主研发的Rentosertib(ISM001-055)正式启动III期临床试验,成为全球首款由AI发现全新靶点、AI设计全新分子并推进至上市前最后验证阶段的候选药物。同月,公司发布业绩预告,2026年上半年实现扭亏为盈,临床与财务数据双双兑现。 放眼整个AI制药行业,2026年,全球AI驱动的新药临床管线增至179个,9个进入III期,剂泰科技的制剂创新、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.